<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="facing numerous challenges, especially cancer. So, the therapeutic arsenal for" exact="cancer" post="should be unremittingly enriched with novel small molecules that"/>
 <result pre="vitro anticancer activity. They possessed good anti-proliferative action towards human" exact="breast cancer" post="T-47D (IC50 range: 0.43â€‰Â±â€‰0.01â€‰âˆ’â€‰35.9â€‰Â±â€‰1.18â€‰ÂµM) and MDA-MB-231 (IC50 range: 0.99â€‰Â±â€‰0.03â€‰âˆ’â€‰34.59â€‰Â±â€‰1.13â€‰ÂµM)"/>
 <result pre="anticancer activity. They possessed good anti-proliferative action towards human breast" exact="cancer" post="T-47D (IC50 range: 0.43â€‰Â±â€‰0.01â€‰âˆ’â€‰35.9â€‰Â±â€‰1.18â€‰ÂµM) and MDA-MB-231 (IC50 range: 0.99â€‰Â±â€‰0.03â€‰âˆ’â€‰34.59â€‰Â±â€‰1.13â€‰ÂµM)"/>
 <result pre="cell lines, whereas they displayed weak activity against the tested" exact="ovarian cancer" post="cell line SKOV-3. Among the studied compounds, the methyltetrahydropyran-bearing"/>
 <result pre="lines, whereas they displayed weak activity against the tested ovarian" exact="cancer" post="cell line SKOV-3. Among the studied compounds, the methyltetrahydropyran-bearing"/>
 <result pre="arsenal with efficient and safe anticancer CDK inhibitors. Keywords Breast" exact="cancer" post="aminopyridazines CDK2 inhibitors apoptosis inducers molecular docking cell cycle"/>
 <result pre="a result of chemicals, viruses, smoking, or diet. Complications of" exact="cancer" post="disease lead to death if left without treatment1. As"/>
 <result pre="without treatment1. As a serious health problem, mortality due to" exact="cancer" post="is expected to surpass that attributable to cardiovascular disorders"/>
 <result pre="die per year, whereas about more than 26 million new" exact="cancer" post="cases and 17 million cancer-related deaths are estimated to"/>
 <result pre="reached per year by 20302. Accordingly, the therapeutic arsenal for" exact="cancer" post="treatment should be urgently enriched with novel small molecules"/>
 <result pre="compound III (Figure 2) elicited excellent cytotoxic activity towards human" exact="colon cancer" post="HT-29 cell line22, whereas compound IV (Figure 2) emerged"/>
 <result pre="III (Figure 2) elicited excellent cytotoxic activity towards human colon" exact="cancer" post="HT-29 cell line22, whereas compound IV (Figure 2) emerged"/>
 <result pre="derivatives here reported; 11aâ€&quot;r will be evaluated against three human" exact="cancer" post="cell lines, namely, T-47D and MDA-MB-231 (breast cancers), and"/>
 <result pre="analysis as well as Anx V-FITC apoptosis assay in both" exact="breast cancer" post="(T-47D and MDA-MB-231) cell lines. Finally, an in silico"/>
 <result pre="as well as Anx V-FITC apoptosis assay in both breast" exact="cancer" post="(T-47D and MDA-MB-231) cell lines. Finally, an in silico"/>
 <result pre="11aâ€&quot;r were assessed for their anti-proliferative potential towards three human" exact="cancer" post="cell lines, namely, T-47D (breast cancer), MDA-MB-231 (breast cancer)"/>
 <result pre="whereas T-47D is considered as hormone-receptor positive and HER2 negative" exact="breast cancer" post="cell line. The IC50 values for target pyridazines 11aâ€&quot;r"/>
 <result pre="T-47D is considered as hormone-receptor positive and HER2 negative breast" exact="cancer" post="cell line. The IC50 values for target pyridazines 11aâ€&quot;r"/>
 <result pre="possessed excellent to moderate anticancer action against the two tested" exact="breast cancer" post="(T-47D and MDA-MB-231) cell lines, whereas they displayed weak"/>
 <result pre="excellent to moderate anticancer action against the two tested breast" exact="cancer" post="(T-47D and MDA-MB-231) cell lines, whereas they displayed weak"/>
 <result pre="they displayed weak to non-significant cytotoxic impact against the tested" exact="ovarian cancer" post="(SKOV-3) cell line, Table 1. Nonetheless, it was noted"/>
 <result pre="displayed weak to non-significant cytotoxic impact against the tested ovarian" exact="cancer" post="(SKOV-3) cell line, Table 1. Nonetheless, it was noted"/>
 <result pre="pyridazines 11aâ€&quot;r exhibited differential activities against the two tested human" exact="breast cancer" post="cell lines; 8 out of 18 compounds were more"/>
 <result pre="11aâ€&quot;r exhibited differential activities against the two tested human breast" exact="cancer" post="cell lines; 8 out of 18 compounds were more"/>
 <result pre="1.57â€‰Â±â€‰0.05â€‰âˆ’â€‰35.9â€‰Â±â€‰1.18â€‰ÂµM). Concerning the anti-proliferative activity of target pyridazines 11aâ€&quot;r against" exact="breast cancer" post="T-47D cell line, the results indicated that the growth"/>
 <result pre="Concerning the anti-proliferative activity of target pyridazines 11aâ€&quot;r against breast" exact="cancer" post="T-47D cell line, the results indicated that the growth"/>
 <result pre="as the unique submicromolar growth inhibitor herein reported towards both" exact="breast cancer" post="T-47D and MDA-MB-231 cell lines. In addition, pyridazines 11d,"/>
 <result pre="the unique submicromolar growth inhibitor herein reported towards both breast" exact="cancer" post="T-47D and MDA-MB-231 cell lines. In addition, pyridazines 11d,"/>
 <result pre="study, the efficient anti-proliferative activities of target pyridazines 11a-r towards" exact="breast cancer" post="cell lines promoted us to explore and get insights"/>
 <result pre="the efficient anti-proliferative activities of target pyridazines 11a-r towards breast" exact="cancer" post="cell lines promoted us to explore and get insights"/>
 <result pre="in cell cycle progression and/or induction of apoptosis in both" exact="breast cancer" post="T-47D and MDA-MB-231 cells. As a reliable tool, the"/>
 <result pre="cell cycle progression and/or induction of apoptosis in both breast" exact="cancer" post="T-47D and MDA-MB-231 cells. As a reliable tool, the"/>
 <result pre="and 11m; the most potent cytotoxic agents towards both examined" exact="breast cancer" post="cell lines (Table 1). As results indicated, pyridazines 11l"/>
 <result pre="11m; the most potent cytotoxic agents towards both examined breast" exact="cancer" post="cell lines (Table 1). As results indicated, pyridazines 11l"/>
 <result pre="11l and 11m to trigger apoptosis in T-47D and MDA-MB-231" exact="cancer" post="cells. Figure 3. Influence of pyridazines 11l and 11â€‰m"/>
 <result pre="and 11â€‰m on the distribution of cell cycle phases in" exact="breast cancer" post="T-47D (A) and MDA-MB-231 (B) cells. Asterisk indicates a"/>
 <result pre="11â€‰m on the distribution of cell cycle phases in breast" exact="cancer" post="T-47D (A) and MDA-MB-231 (B) cells. Asterisk indicates a"/>
 <result pre="potent anti-proliferative agents herein reported, has been assessed in both" exact="breast cancer" post="T-47D and MDA-MB-231 cell lines using Annexin V FITC/PI"/>
 <result pre="anti-proliferative agents herein reported, has been assessed in both breast" exact="cancer" post="T-47D and MDA-MB-231 cell lines using Annexin V FITC/PI"/>
 <result pre="well as their efficient anti-proliferative actions towards both the examined" exact="breast cancer" post="cell lines (Table 1), pyridazines 11e, 11h, 11l, and"/>
 <result pre="as their efficient anti-proliferative actions towards both the examined breast" exact="cancer" post="cell lines (Table 1), pyridazines 11e, 11h, 11l, and"/>
 <result pre="and evaluated for inÂ vitro anticancer activity against three human" exact="cancer" post="cell lines, namely, T-47D (breast cancer), MDA-MB-231 (breast cancer)"/>
 <result pre="reported by the author(s). References References 1PadmaVV.An overview of targeted" exact="cancer" post="therapy. Biomedicine2015;5:19â€&quot;6.26613930 2SiegelRL, MillerKD, JemalA.Cancer statistics 2016. CA: Cancer"/>
 <result pre="TurnerNC, KnudsenES.The history and future of targeting cyclin-dependent kinases in" exact="cancer" post="therapy. Nat Rev Drug Discov2015;14:130â€&quot;46.25633797 7SpringLM, WanderSA, ZangardiM, BardiaA.CDK"/>
 <result pre="carboplatin/etoposide as first-line therapy in patients with extensive-disease small cell" exact="lung cancer." post="J Thorac Oncol2019;14:701â€&quot;11.30677506 9NiuY, XuJ, SunT.Cyclin-dependent kinases 4/6 inhibitors"/>
 <result pre="cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human" exact="breast cancer." post="Int J Mol Sci2020;21:1960. 38DainaA, MichielinO, ZoeteV.SwissADME: a free"/>
 <result pre="49EldehnaWM, HassanGS, Al-RashoodST, et al.Marine-inspired bis-indoles possessing antiproliferative activity against" exact="breast cancer;" post="design, synthesis, and biological evaluation. Mar Drugs2020;18:190. 50SaidMA, EldehnaWM,"/>
</results>
